Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/20/2009

VIENNA, Va., Feb. 20 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI Corporation (NYSE Alternext US: CVM) to its shareholders:

Dear Fellow Shareholders:

I am writing today to provide you with a review of 2008 as well as to update you on our plans for dealing with the current financial downturn. In looking back at the last year, I see a year of meaningful accomplishments which put CEL-SCI in a valuable position, and among a very select group of companies that have a completely novel medicine with blockbuster potential ready to go into a Phase III clinical trial.

Key Company highlights of 2008:

  • We extended our Multikine licensing agreement with Orient EuroPharma of Taiwan (a leading pharmaceutical company in Taiwan) to cover additional countries in the Far East. Orient EuroPharma will also participate in and pay for part of our Phase III trial.

  • At the end of 2008 we took delivery of the Multikine manufacturing facility in Baltimore. This facility will supply Multikine for the Phase III clinical trial as well as commercial s
    '/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
2. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
3. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
4. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
5. CEL-SCI Corporation Reports First Quarter Financial Results
6. CEL-SCI Corporation Announces 2007 Financial Results
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ATLANTA , July 6, 2015 Celtaxsys, ... anti-inflammatory therapeutics, including those with rare and orphan inflammatory ... from the U.S. Food and Drug Administration (FDA) to ... drug candidate, acebilustat (CTX-4430), in adult CF patients in ... in Europe will be filed ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
(Date:7/5/2015)... July 6, 2015 Nihon University is ... on Medical-Engineering Collaboration "Medicine Definitely Jumps Up ... 2015 in Tokyo, Japan . ... applied research will present their achievements and future ... new industry produced with 8K technology. ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3
... Corporation (NYSE: SHP ) ("ShangPharma" or the "Company"), ... company, today announced that it will release its unaudited financial ... on May 19, 2011. Management will host a conference call ... May 19, 2011 (8:00pm Beijing time on May 19, 2011). ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the ... branded Traditional Chinese Medicine ("TCM") consumer products, today ... Anhui Province in eastern China. The Company,s value-oriented ... "Yang Yang Ba" health drink are now available ...
Cached Medicine Technology:ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011 2Nutrastar Distribution Spreads into Anhui Province 2Nutrastar Distribution Spreads into Anhui Province 3
(Date:7/6/2015)... ... July 06, 2015 , ... University of Pittsburgh Cancer Institute ... cancer testing to reflect newly available tests that better incorporate personalized medicine into diagnosing ... interpret thyroid cancer tests is published in the July issue of the scientific journal ...
(Date:7/6/2015)... ... 06, 2015 , ... Invitation to Cover: , Most African ... large gap between the unmet health priorities in the region and the kind ... unnecessary or ineffective treatments or procedures. , This milestone conference, sponsored by Columbia ...
(Date:7/6/2015)... ... July 06, 2015 , ... doTERRA, the leading global essential oils company, ... Most recently, Jowers held the position as Director of the Hinckley Institute at the ... decade building the institute, Jowers states that he was ready for a new challenge, ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) and ... toward self-sufficiency. FESCO was created especially to provide emergency services and support for ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... World ... patients the opportunity to achieve their ideal appearance through comprehensive treatment solutions. Individuals that ... goals with the doctor and receive a plan that resolves each of their needs. ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... outcomes of medical tests whose results are pending at ... and can lead to serious medical errors in post-hospitalization ... from the Regenstrief Institute and the Indiana University School ... grossly inadequate at documenting both tests with pending results ...
... , , , ... Senate health care reform bills aren,t just for wonky policy experts," say ... Analyst Jordan Osserman. "They translate to real differences in Americans, lives." , ... Beach Post, " THE PROGNOSIS FOR REFORM," Weiner and Osserman contend, "With ...
... elderly, researchers say , FRIDAY, Aug. 7 (HealthDay News) ... exercise endurance by up to 16 percent, a new ... nitrate in beetroot juice reduces oxygen uptake to a ... The findings could benefit endurance athletes, elderly people and ...
... , CHICAGO, Aug. 7 Allscripts (Nasdaq: ... that a purported class action complaint had been filed in the ... the Company and certain of its executive officers. The complaint alleges ... failed to disclose certain facts about the Company,s business, and on ...
... , NEW YORK, Aug. 7 ... additional vaccines beyond those received when they were infants or small ... estimates, most pre-teens and teens do not have all the vaccinations ... for certain diseases and protection from some childhood vaccines can wear ...
... 7 Averaging 2,700 patients daily ... information call center, Hospice Partners On Call has selected 1Vault ... to safeguard its powerful server infrastructure and guarantee call center ... decided to move their back-up servers to our secure location, ...
Cached Medicine News:Health News:Fumbled handoffs can lead to medical errors 2Health News:Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, 'Disappointed' by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bill's 'Prognosis' 2Health News:Beetroot Juice May Boost Stamina 2Health News:Allscripts Notified of Purported Class Action Lawsuit 2Health News:Allscripts Notified of Purported Class Action Lawsuit 3Health News:Photo: New Survey Results Show Most Moms Are Aware Their Pre-teens and Teens Need Vaccines 2Health News:Photo: New Survey Results Show Most Moms Are Aware Their Pre-teens and Teens Need Vaccines 3Health News:Hospice Partners On Call Selects Category 5 Hurricane Rated 1Vault Networks to Safeguard Server and Call Center Infrastructure 2
... growth factor I or somatomedin-C, is a ... has potent growth promoting activity. IGF-I is ... In the diagnosis of growth disorders, measurements ... assessment of growth hormone secretion. A normal ...
... 2000 assays are designed ... IMMULITE 2000, a high-throughput, ... analyzer. IMMULITE 2000 offers ... and a rapidly expanding ...
... IMMULITE and IMMULITE 1000 ... with the IMMULITE and IMMULITE ... analyzers which offer simplicity in ... systems can be found in ...
... For The Detection Of ... Of C-Peptide Measurement:, ... hypoglycemia , Assisting in ... mellitus , Differentiating insulin ...
Medicine Products: